Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dextroamphetamine + amphetamine (Takeda)
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mixed amphetamine salts is a central nervous system (CNS) stimulant medication primarily indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) and narcolepsy. It consists of a specific 3:1 ratio of dextroamphetamine and levoamphetamine salts, typically formulated as a combination of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate. The drug functions as a sympathomimetic amine that increases the synaptic concentrations of norepinephrine and dopamine. Its mechanism of action involves the inhibition of monoamine reuptake via the dopamine transporter (DAT) and norepinephrine transporter (NET), as well as the promotion of neurotransmitter release from presynaptic neurons through interaction with the trace amine-associated receptor 1 (TAAR1) and the vesicular monoamine transporter 2 (VMAT2). Originally developed by Shire (now part of Takeda), it is available in both immediate-release and extended-release formulations.
- Brand names
- AdderallAdderall XRMydayisAdzenys XR-ODTDyanavel XR
- Other names
- mixed amphetamine saltsMASMAS-IRMAS-XRamphetamine mixed saltsmixed salts of a single-entity amphetamine product
02
Targets
NET (Norepinephrine Transporter)TAAR1 (Trace amine-associated receptor 1)VMAT2 (Vesicular monoamine transporter 2)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on dextroamphetamine + amphetamine (Takeda).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dextroamphetamine + amphetamine (Takeda).